Manufacturing, Scale-up & Supply Chain
- The manufacturing readiness gap
- Why promising conjugates stall between discovery and scalable production
- Geopolitics and supply-chain strategy to de-risk access to payloads, linkers, and antibodies
- In-house vs CDMO, and how the outsourcing landscape is shaping manufacturing decisions
- Designing manufacturing for a pipeline of increasingly diverse and complex formats
- Cost of goods as a strategic lever for ADC commercial viability and patient access
- What ADC scale-up has taught the industry, and how transferable those lessons are to new modalities
- Building flexibility through platform facilities and processes for a multi-modality future